title: B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in Greece.
abstract: OBJECTIVE
  Leptin and adiponectin are two well-studied adipokines in relation to malignancies. In this study, we examined the association between leptin/adiponectin and risk of B-cell chronic lymphocytic leukemia (B-CLL), as well as the relationships between adipokines and several established prognostic factors of B-CLL.
  
  
  METHODS
  Ninety-five patients with incident B-CLL and 95 hospital controls matched on age and gender were studied between 2001 and 2007, and blood samples were collected. Leptin, total and high molecular weight adiponectin, and prognostic markers of B-CLL were determined.
  
  
  RESULTS
  Cases had a higher body mass index (BMI) than controls (p = 0.01) and lower levels of leptin (p < 0.01). Significantly more cases than controls presented a family history of lymphohematopoietic cancer (LHC) (p = 0.01). Higher serum leptin levels were associated with lower risk of B-CLL adjusting for age, gender, family history of LHC, BMI and serum adiponectin; the multivariate odds ratio comparing highest to lowest tertile was 0.05 (95% CI 0.01-0.29, p trend < 0.001); Adiponectin was not significantly different between cases and controls.
  
  
  CONCLUSIONS
  Leptin was found to be inversely associated with risk of CLL but in contrast to prior studies of CLL and hematologic malignancies, this study found no significant association between CLL and adiponectin.
authors.affiliation: Department of Clinical Biochemistry, Medical School, University of Athens, Attikon General University Hospital, Athens, Greece.
authors.forename: Maria
authors.initials: M
authors.lastname: Dalamaga
authors.forename: Bradley H
authors.initials: BH
authors.lastname: Crotty
authors.forename: Jessica
authors.initials: J
authors.lastname: Fargnoli
authors.forename: Evangelia
authors.initials: E
authors.lastname: Papadavid
authors.forename: Antigoni
authors.initials: A
authors.lastname: Lekka
authors.forename: Maria
authors.initials: M
authors.lastname: Triantafilli
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Karmaniolas
authors.forename: Ilias
authors.initials: I
authors.lastname: Migdalis
authors.forename: Amalia
authors.initials: A
authors.lastname: Dionyssiou-Asteriou
authors.forename: Christos S
authors.initials: CS
authors.lastname: Mantzoros
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006115:Greece; D006801:Humans; D020738:Leptin / Q000097:blood*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011863:Radioimmunoassay; D012307:Risk Factors
chemical_list: D052242:Adiponectin; D014408:Biomarkers, Tumor; D020738:Leptin
references.citation: J Leukoc Biol. 2000 Oct;68(4):437-46
references.pmid: 11037963
references.citation: Exp Oncol. 2006 Sep;28(3):241-4
references.pmid: 17080020
references.citation: Egypt J Immunol. 2003;10(1):57-66
references.pmid: 15719623
references.citation: Int J Hematol. 2006 Apr;83(3):254-8
references.pmid: 16720558
references.citation: Haematologica. 2002 Jun;87(6):584-95
references.pmid: 12031914
references.citation: Br J Cancer. 2006 Jan 16;94(1):156-60
references.pmid: 16404369
references.citation: J Biol Chem. 2003 Oct 10;278(41):40352-63
references.pmid: 12878598
references.citation: Cancer Res. 2006 Dec 1;66(23):11462-70
references.pmid: 17145894
references.citation: J Exp Clin Cancer Res. 2006 Dec;25(4):537-41
references.pmid: 17310845
references.citation: Endocr Relat Cancer. 2007 Sep;14(3):713-20
references.pmid: 17914101
references.citation: Br J Cancer. 2006 May 8;94(9):1221-5
references.pmid: 16570048
references.citation: Nat Med. 2001 Aug;7(8):941-6
references.pmid: 11479627
references.citation: Br J Haematol. 1998 Aug;102(3):740-5
references.pmid: 9722301
references.citation: Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14564-8
references.pmid: 8962092
references.citation: Int J Cancer. 2008 Mar 15;122(6):1418-21
references.pmid: 18027857
references.citation: Leuk Res. 2003 Oct;27(10):871-6
references.pmid: 12860003
references.citation: J Clin Endocrinol Metab. 1996 Sep;81(9):3419-23
references.pmid: 8784108
references.citation: Ann Oncol. 1999 Dec;10(12):1419-32
references.pmid: 10643532
references.citation: Eur J Cancer. 2008 Aug;44(12):1744-53
references.pmid: 18515085
references.citation: Expert Opin Investig Drugs. 2006 Aug;15(8):917-31
references.pmid: 16859394
references.citation: Int J Hematol. 2008 Nov;88(4):374-380
references.pmid: 18818986
references.citation: Blood. 2000 Sep 1;96(5):1723-32
references.pmid: 10961870
references.citation: J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8
references.pmid: 17192291
references.citation: Oncology. 2007;73(1-2):26-32
references.pmid: 18337619
references.citation: Am J Epidemiol. 2002 Sep 15;156(6):527-35
references.pmid: 12226000
references.citation: Nature. 2003 Jun 12;423(6941):762-9
references.pmid: 12802337
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6793-9
references.pmid: 16203766
references.citation: Cancer. 1981 Jul 1;48(1):198-206
references.pmid: 7237385
references.citation: Endocr Rev. 2005 May;26(3):439-51
references.pmid: 15897298
references.citation: Am J Clin Nutr. 2007 Sep;86(3):s858-66
references.pmid: 18265479
references.citation: J Biol Chem. 2004 Jul 16;279(29):30817-22
references.pmid: 15123605
references.citation: Leuk Lymphoma. 2000 Feb;36(5-6):457-61
references.pmid: 10784389
references.citation: Cell Res. 2007 Apr;17(4):280-2
references.pmid: 17404599
references.citation: Blood. 1996 Jun 15;87(12):4990-7
references.pmid: 8652811
references.citation: Dig Dis Sci. 2008 Mar;53(3):597-605
references.pmid: 17763959
references.citation: Cancer Causes Control. 2001 Jan;12(1):13-21
references.pmid: 11227921
references.citation: J Immunol. 2007 Mar 15;178(6):3511-20
references.pmid: 17339446
references.citation: Int J Hematol. 2002 Dec;76(5):446-52
references.pmid: 12512839
references.citation: Bone. 2004 Oct;35(4):842-9
references.pmid: 15454091
references.citation: Physiol Behav. 2006 Jun 30;88(3):249-56
references.pmid: 16782141
references.citation: Cancer Causes Control. 2009 Mar;20(2):193-9
references.pmid: 18814045
references.citation: Blood. 1999 Mar 1;93(5):1668-76
references.pmid: 10029596
references.citation: Endocrinology. 2005 Feb;146(2):790-6
references.pmid: 15528304
references.citation: Int J Cancer. 2007 Oct 1;121(7):1564-70
references.pmid: 17443495
references.citation: Curr Treat Options Oncol. 2002 Jun;3(3):225-31
references.pmid: 12057068
references.citation: J Immunol. 2003 Nov 15;171(10):5091-9
references.pmid: 14607907
references.citation: Curr Biol. 1996 Sep 1;6(9):1170-80
references.pmid: 8805376
references.citation: N Engl J Med. 1996 Feb 1;334(5):292-5
references.pmid: 8532024
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81
references.pmid: 14983034
references.citation: Eur J Cancer Care (Engl). 2004 Jul;13(3):279-87
references.pmid: 15196232
references.citation: J Clin Invest. 2003 May;111(9):1409-21
references.pmid: 12727933
references.citation: Br J Haematol. 1997 Sep;98(4):934-9
references.pmid: 9326192
references.citation: Horm Metab Res. 2007 Jan;39(1):9-13
references.pmid: 17226107